Literature DB >> 12511405

Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations.

Francisca I Camacho1, Patrocinio Algara, Antonia Rodríguez, Elena Ruíz-Ballesteros, Manuela Mollejo, Nerea Martínez, José A Martínez-Climent, Marcos González, Marisol Mateo, Alessia Caleo, Margarita Sánchez-Beato, J Menárguez, Javier García-Conde, Francesc Solé, Elias Campo, Miguel A Piris.   

Abstract

This study explores whether the presence of somatic mutations or a biased use of IgV(H) genes were associated with the clinical features in a series of 96 patients with mantle cell lymphoma (MCL). The cases were studied by seminested polymerase chain reaction using primers from the FR1 and J(H) regions. There was an unexpectedly high frequency of somatic mutations, with 29 of 103 sequences showing more than 2% of mutations. Biased usage of specific V(H) segments was also found; the most widely used genes in this series were V(H)3-21 (10 cases), V(H)3-23 (9 cases), V(H)4-34 (11 cases), and V(H)4-59 (9 cases). V(H) mutation frequency, taking into account different thresholds, did not distinguish different overall survival probabilities. Nevertheless, a more frequent use of V(H)3-21 or V(H)4-59 (8 of 18) was observed in the group of long-term survivors (18 cases > 5 years; P <.01). None of these long-term survivors presented the V(H)3-23 gene rearrangement. As in other lymphoproliferative disorders, the expression of CD38 or p53 or both was associated with a poorer survival probability. This nonrandom usage of IgV(H) segments suggests that specific antigens may play a pathogenically relevant role in the genesis or progression of subsets of MCL cases and may help in distinguishing a significant group of MCL long-term survivors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511405     DOI: 10.1182/blood-2002-11-3456

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

2.  Parallel gene expression profiling of mantle cell lymphoma - how do we transform 'omics data into clinical practice.

Authors:  Ek Sara; Carl Ak Borrebaeck
Journal:  Curr Genomics       Date:  2007-05       Impact factor: 2.236

3.  Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.

Authors:  Carlo Visco; Sylvia Hoeller; Jeffrey T Malik; Zijun Y Xu-Monette; Michele L Wiggins; Jessica Liu; Warren G Sanger; Zhongfeng Liu; Julie Chang; Erik A Ranheim; Joel F Gradowski; Sergio Serrano; Huan-You Wang; Qingquan Liu; Sandeep Dave; Brian Olsen; Randy D Gascoyne; Elias Campo; Steven H Swerdlow; Wing C Chan; Alexander Tzankov; Ken H Young
Journal:  Am J Surg Pathol       Date:  2011-02       Impact factor: 6.394

4.  TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.

Authors:  Hua-Jie Dong; Li-Tao Zhou; Cheng Fang; Lei Fan; Dan-Xia Zhu; Yin-Hua Wang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-11-06       Impact factor: 3.064

Review 5.  Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis.

Authors:  Sarah H Walsh; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

6.  An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma.

Authors:  Mauricio Zapata; Steven D Budnick; Rodolfo Bordoni; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2010-03-20

7.  Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.

Authors:  Patricia Pérez-Galán; Helena Mora-Jensen; Marc A Weniger; Arthur L Shaffer; Edgar G Rizzatti; Colby M Chapman; Clifton C Mo; Lawrence S Stennett; Christoph Rader; Poching Liu; Nalini Raghavachari; Maryalice Stetler-Stevenson; Constance Yuan; Stefania Pittaluga; Irina Maric; Kieron M Dunleavy; Wyndham H Wilson; Louis M Staudt; Adrian Wiestner
Journal:  Blood       Date:  2010-10-18       Impact factor: 22.113

Review 8.  Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.

Authors:  Jia Ruan; Peter Martin
Journal:  Curr Hematol Malig Rep       Date:  2016-06       Impact factor: 3.952

9.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features.

Authors:  Alba Navarro; Guillem Clot; Cristina Royo; Pedro Jares; Anastasia Hadzidimitriou; Andreas Agathangelidis; Vasilis Bikos; Nikos Darzentas; Theodora Papadaki; Itziar Salaverria; Magda Pinyol; Xavier Puig; Jara Palomero; Maria Carmela Vegliante; Virgina Amador; Alejandra Martinez-Trillos; Lenka Stefancikova; Adrian Wiestner; Wyndham Wilson; Christiane Pott; Maria Jose Calasanz; Nicola Trim; Wendy Erber; Birgitta Sander; German Ott; Andreas Rosenwald; Dolors Colomer; Eva Giné; Reiner Siebert; Armando Lopez-Guillermo; Kostas Stamatopoulos; Sílvia Beà; Elías Campo
Journal:  Cancer Res       Date:  2012-08-20       Impact factor: 12.701

10.  BCL6, MUM1, and CD10 expression in mantle cell lymphoma.

Authors:  Gabriela Gualco; Lawrence M Weiss; William J Harrington; Carlos E Bacchi
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.